We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Chronic Comorbidities Are Prevalent Among People with Chagas Disease

By LabMedica International staff writers
Posted on 12 Dec 2019
Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the protist Trypanosoma cruzi. More...
It is spread mostly by insects known as Triatominae, or "kissing bugs". The symptoms change over the course of the infection.

Although Chagas disease is often thought of as a parasitic infection that predominantly affects rural areas of Latin America, it should be noted that a large epidemiological burden of cases in the USA, including an estimated 70,000 in California, 37,000 in Texas, 18,000 in Florida, and 17,000 in New York, none of which included undocumented individuals.

Scientists from the Center of Excellence for Chagas Disease, Sylmar, CA, USA) and their colleagues performed a retrospective chart review of 221 patients from their center, who were a mean age of about 56, and had been in the USA for an average of 37 years. More than half of the patients were women, about half were from El Salvador, with about a quarter from Mexico, and a little less than half were ages 50-69. A little over 30% of these patients had cardiomyopathy. The most common comorbidity among these patients was hypertension (43%), followed by obesity (39.6%) and hyperlipidemia (30.6%). Only 30% of patients had no comorbidities, while 9% had five or more in this cohort.

Men had a significantly higher number of comorbidities compared with women (2.22 versus 1.63, respectively), and the same was observed for patients with cardiomyopathy versus patients with no cardiomyopathy (3.06 versus 1.34). The team noted that comorbidities increased with age, with patients ages 70 and older having a mean of almost three comorbidities compared to younger patients ages 18-39 with less than one. They also noted that about 63% are living below the federal poverty level, 66% have less than a high school education, and 72% rely on public insurance in California. In a multivariable linear regression, age and presence of Chagas cardiomyopathy were significantly associated with the number of comorbidities.

Salvador Hernandez, MD, project manager at the center, said, “That of patients who are infected with Chagas disease, 30%-40% will progress to the chronic phase of the disease, which does not present until 20-30 years after the initial infection. Of these cases, 60%-70% will have cardiac involvement. This starts as abnormalities on EKG, such as a right bundle branch block or a left anterior fascicular block. These symptoms are followed by slow progressive cardiomyopathy until symptoms of heart failure and sudden death from arrhythmia. At this final stage, the disease becomes irreversible and treatment with anti-parasitic therapy does not alter the disease course. This points to an urgent need for comprehensive care of these patients and for earlier, more proactive screening and treatment of this largely hidden disease.” The study was presented on November 22, 2019 at the American Society of Tropical Medicine and Hygiene Annual meeting held in National Harbor, MD, USA.

Related Links:
Center of Excellence for Chagas Disease


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.